专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明公开

EP1080078A1 HETEROCYCLIC COMPOUNDS AND METHODS TO TREAT CARDIAC FAILURE AND OTHER DISORDERS 有权
标题翻译： HETEROZYCLISCHE衍生物对心力衰竭等疾病的治疗
公开(公告)号：EP1080078A1
公开(公告)日：2001-03-07
申请号：EP99924412.2
申请日：1999-05-21
申请人： SCIOS INC.
发明人： MAVUNKEL, Babu, J. , LIU, David, Y. , SCHREINER, George, F. , LEWICKI, John, A. , PERUMATTAM, John, J.
IPC分类号： C07D235/06 , C07D401/06 , C07D401/14 , C07D209/08 , C07D403/06 , A61K31/445 , A61K31/40 , A61K31/41
CPC分类号： C07D209/08 , C07D235/06 , C07D401/06 , C07D401/14 , C07D403/06
摘要： Compounds of formulae α or β, and the pharmaceutically acceptable salts thereof, wherein each of Z?1 and Z2¿ is independently CR4 or N; where each R4 is independently H or is alkyl (1-6C) or aryl, each of said alkyl or aryl optionally including one or more heteroatoms selected from O, S and N and optionally substituted by one or more of halo, OR, SR, NR¿2?, RCO, COOR, CONR2, OOCR, or NROCR where R is H or alkyl (1-6C), or by one or more CN or =O, or by one or more aliphatic or aromatic 5- or 6-membered rings optionally containing 1-2 heteroatoms; R?1¿ is formula (I); wherein X1 is CO or an isostere thereof; m is 0 or 1; Y is optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl or two Y taken together may form an alkylene (2-3C) bridge; n is 0 or 2; Z3 is CH or N; X2 is CH, CH¿2? or an isostere thereof; and Ar consists of one or two phenyl moieties directly coupled to X?2¿ optionally substituted by halo, nitro, alkyl(1-6C), alkenyl(1-6C), alkynyl(1-6C), CN or CF¿3?, or by RCO, COOR, CONR2, NR2, OR, SR, OOCR or NROCR wherein R is H or alkyl(1-6C) or by phenyl, itself optionally substituted by the foregoing substituents; R?2¿ is H, or is alkyl(1-6C) or aryl, each or said alkyl or aryl optionally including one heteroatome which is O, S or N, and optionally substituted by one or more of halo, OR, SR, NR¿2?, RCO, COOR, CONR2, OOCR, or NROCR where R is H or alkyl(1-6C), alkynyl(1-6C), or by one or more CN or =O, or by one or more aliphatic or aromatic 5- or 6-membered rings optionally containing 1-2 heteroatoms; R?3¿ is H, halo, NO¿2?, alkyl(1-6C), alkenyl(1-6C), alkynyl(1-6C), CN, OR, SR, NR2, RCO, COOR, CONR2, OOCR, or NROCR where R is H or alkyl(1-6C) are disclosed. These compounds are selective inhibitors of p38α kinase.

62. 发明授权

EP0671392B1 Substituierte Propan-Derivate, Verfahren zu ihrer Herstellung und die Anwendung der Verbindungen zur Behandlung von Krankheiten 失效
标题翻译：取代的丙烷衍生物，它们的制备方法和用于治疗疾病的使用所述化合物的方法
公开(公告)号：EP0671392B1
公开(公告)日：2001-02-21
申请号：EP95103046.9
申请日：1995-03-03
申请人： HOECHST AKTIENGESELLSCHAFT
发明人： Schubert, Gerrit, Dr. , Hemmerle, Horst, Dr. , Below, Peter, Dr. , Herling, Andreas, Dr. , Burger, Hans-Jörg, Dr.
IPC分类号： C07D235/06 , C07D471/04 , A61K31/415
CPC分类号： C07D235/06 , C07D471/04

64. 发明公开

EP0973749A1 4-AMINOALKOXY-1H-BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMINE AUTORECEPTOR (D2) AGONISTS 失效
标题翻译： 4-氨基烷氧基-1H-苯并咪唑衍生物，其制备及其作为多巴胺受体AUTO（D2）激动剂
公开(公告)号：EP0973749A1
公开(公告)日：2000-01-26
申请号：EP98902513.5
申请日：1998-01-13
申请人： AMERICAN HOME PRODUCTS CORPORATION
发明人： NELSON, James, Albert , MEWSHAW, Richard, Eric
IPC分类号： C07D235/06 , A61K31/415 , C07D235/08 , C07D235/10 , C07D409/12 , C07D401/12 , A61K31/47
CPC分类号： C07D235/06 , C07D235/08 , C07D235/10 , C07D401/12 , C07D409/12
摘要： This invention relates to D2 dopaminergic compounds of formula (I), wherein R1 is hydrogen, trifluoromethyl, pentafluoroethyl, heptafluoropropyl, straight-chain or branched alkyl group having up to 6 carbons or benzyl optionally substituted by one to three substituents selected from halogen, amino, nitro, hydroxy, C¿1?-C6 alkoxy; R?2¿ is hydrogen or C¿1?-C6 alkyl. R3 is hydrogen, straight-chain or branched alkyl group having up to 10 carbon atoms, cyclohexylmethyl, -(CH2)mAr, where Ar is phenyl, thienyl, furanyl, or pyridinyl, each optionally substituted by one to two substituents selected from halogen, C1-C6 alkoxy, trifluoromethyl or C1-C6 alkyl; or NR?2R3¿ is 1,2,3,4-tetrahydroquinolin-1-yl or 1,2,3,4-tetrahydroisoquinolin-2-yl; Y = halogen, lower alkyl, amino, and lower alkoxy; n = 1-5; or a pharmaceutically acceptable salt thereof. These D¿2? dopaminergic compounds are useful in the treatment of schizophrenia, Parkinson's disease, Tourette's syndrome, and drug or alcohol addiction.

65. 发明授权

EP0616807B1 Benzimidazole useful in the treatment of central nervous system disorders 失效
标题翻译：对于治疗中枢神经系统的苯并咪唑可用的疾病
公开(公告)号：EP0616807B1
公开(公告)日：1998-07-08
申请号：EP94610012.0
申请日：1994-03-11
申请人： NEUROSEARCH A/S , MEIJI SEIKA KAISHA LTD.
发明人： Axelsson, Oskar , Teuber, Lene , Wätjen, Frank
IPC分类号： A61K31/415 , A61K31/44 , C07D401/10 , C07D405/14 , C07D403/10 , C07D235/06 , C07D487/06 , C07D471/06 , C07D405/00 , C07D413/00 , C07D401/00 , C07D513/04
CPC分类号： C07D235/02 , C07D231/12 , C07D233/56 , C07D235/06 , C07D249/08 , C07D401/04 , C07D401/10 , C07D401/14 , C07D405/10 , C07D405/14 , C07D413/10 , C07D413/14 , C07D471/04 , C07D471/06 , C07D487/06 , C07D513/04

66. 发明公开

EP0820990A2 Nouveaux dérivés de benzimidazole, de benzoxazole et de benzothiazole, utilisables comme inhibiteurs de l'interleukine 1bêta 失效
标题翻译： Neue Benzimidazol-，Benzoxazol- und Benzothiazolderivate，welche als Inhibitoren des Interleukin 1beta verwendbar sind
公开(公告)号：EP0820990A2
公开(公告)日：1998-01-28
申请号：EP97401789.9
申请日：1997-07-24
申请人： ADIR ET COMPAGNIE
发明人： de Nanteuil, Guillaume , Portevin, Bernard , Bonnet, Jacqueline , Fradin, Armel
IPC分类号： C07D235/12 , C07D235/06 , C07D235/10 , A61K31/415 , C07D235/14 , C07D401/12 , C07D401/06 , C07D401/14 , C07D403/12
CPC分类号： C07D401/06 , C07D235/06 , C07D235/10 , C07D235/12 , C07D235/14 , C07D401/12 , C07D401/14 , C07D403/12
摘要： Composé de formule (I) :
dans laquelle :

R 1 représente un atome d'halogène, un groupement hydroxy, alkoxy, trihalogénométhyle, amino, mercapto, alkylthio, trialkylammonium, aryloxy, arylthio, arylsulfonyle, arylsulfonyloxy, cycloalkyloxy, cycloalkylthio, bicycloalkyloxy ou bicycloalkylthio,
R a , R b , identiques ou différents, représentent un atome d'hydrogène ou un groupement alkyle,
X représente un atome d'oxygène ou de soufre ou un groupement NR,
Y représente un atome d'oxygène ou de soufre, un groupement amino, SO 2 ou l'un des groupements tels que définis dans la description,
R 2 représente un groupement aryle éventuellement substitué,
leurs isomères ainsi que leurs sels d'addition à un acide ou à une base pharmaceutiquement acceptable.
Médicaments.
摘要翻译：式（I）的苯并咪唑，苯并恶唑和苯并噻唑衍生物，其异构体和盐是新的。 R1 =卤素，OH，1-6C烷氧基（任选被芳基取代），三卤代甲基，氨基（任选被1个或多个任选取代的烷基或芳基取代），SH，1-6C烷硫基，1-6C三烷基铵，，芳硫基，芳基磺酰基，芳基 - 磺酰氧基，3-7C环烷氧基或环烷硫基，或6-8C双环烷氧基或二环烷硫基（均可任选被芳基取代）; Ra，Rb = H或1-6C烷基; X = O，S或NR; R = H或1-6C烷基; Y =（CH2）mZ（CH2）n; m，n = 0-2; Z = O，S，任选被烷基，SO 2，CHOH，CH 2或CH（CH 2 OH）取代的氨基; 并且R 2 =任选取代的芳基。

69. 发明公开

EP0764640A1 Selective beta3 adrenergic agonists 失效
标题翻译： Trennscharfe Beta-3-adrenergische Agonisten
公开(公告)号：EP0764640A1
公开(公告)日：1997-03-26
申请号：EP96306851.5
申请日：1996-09-20
申请人： ELI LILLY AND COMPANY
发明人： Jesudason, Cynthia Darshini , Matthews, Donald Paul , McDonald, John Hampton , Neel, David Andrew , Rito, Christopher John , Shuker, Anthony John , Bell, Michael Gregory , Crowell, Thomas Alan , Droste, Christine Ann , Winter, Mark Alan
IPC分类号： C07D235/26 , C07D235/06 , C07D403/12 , C07D401/12 , C07D409/12 , C07D285/10 , C07D417/12 , C07D263/58 , C07D413/12 , C07D209/08 , C07D249/18 , A61K31/44
CPC分类号： C07D209/08 , A61K31/404 , A61K31/4192 , C07D235/06 , C07D235/26 , C07D249/18 , C07D263/58 , C07D285/14 , C07D401/12 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要： The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective β3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and method of treating type II diabetes, comprising administering to a mammal in need thereof compounds of the Formulas I and II:
摘要翻译：本发明在医药领域，特别是在治疗II型糖尿病和肥胖症方面。更具体地，本发明涉及用于治疗II型糖尿病和肥胖症的选择性β3肾上腺素能受体激动剂。本发明提供了治疗II型糖尿病的化合物和方法，包括向需要的哺乳动物施用式I和II的化合物：

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式